ClinicalTrials.gg
CompletedNCT03370848Updated Dec 12, 2017

Effects of Psyllium on Niacin Tolerability

A Phase 4 interventional study of Psyllium and Aspirin in Flushing, Hyperlipidemias and Dyslipidemias, sponsored by VA Greater Los Angeles Healthcare System. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-12.

Sponsored by VA Greater Los Angeles Healthcare System · Phase 4, Interventional, and Supportive care

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether psyllium is effective in reducing flushing due to niacin and also to measure the effect of niacin on cholesterol levels.

02

Conditions studied

  • Flushing
  • Hyperlipidemias
  • Dyslipidemias

Keywords

  • Niacin
  • Psyllium
  • Dietary fiber
03

In context

Flushing

22 studies on the registry are indexed under Flushing; 5 are open to participants now.

This study's enrollment of 26 is below the median of 90 across 19 interventional studies indexed under Flushing.

Browse Flushing studies →

Lead sponsor

VA Greater Los Angeles Healthcare System is the lead sponsor of 32 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are starting ER niacin for clinical indication by a healthcare provider
  • No prior use of psyllium for the past 2 months
  • No prior use of niacin for the past 3 months
  • Ability to give
  • Must be reachable by telephone

Exclusion criteria

Exclusion Criteria:

  • Known to ER niacin, aspirin or psyllium (including: presence of nausea, vomiting, abdominal pain, intestinal obstruction, or fecal impaction; known to ER niacin, aspirin or psyllium; severe hepatic dysfunction, transaminitis; history of gastrointestinal bleed attributable to aspirin induced gastritis)
  • Patient who are unable to perform assessment of flushing using the standardized scales or questionnaires
  • Patients who are pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Psyllium plus Aspirin and Niacin ER

    Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks. Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER Psyllium 1.7gm wafers - take 2 wafers (3.4 grams total) along with aspirin 30 minutes prior to niacin ER

    Dietary Supplement: Psyllium · Drug: Aspirin

  • Active comparator
    Aspirin and Niacin ER

    Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks. Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER

    Drug: Aspirin

Interventions

  • Dietary supplementPsyllium

    Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER

    Also known as: Metamucil, Cilium, Fiberall

  • Aspirin 325 mg tablet 30 minutes prior to niacin ER

    Also known as: Bayer, Ecotrin

06

What researchers measure

Primary outcomes

  1. Global Flushing Severity Score

    Time frame: up to 6 weeks

Secondary outcomes

  1. HDL

    Time frame: Baseline, & end of week 6

  2. LDL

    Time frame: Baseline, & end of week 6

07

Study locations

1 site
  • VA West Los Angeles Medical Center
    Los Angeles, California 90073, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03370848
Lead sponsor
VA Greater Los Angeles Healthcare System
Responsible party
Sponsor
First posted
Dec 12, 2017
Start date
Mar 2009
Primary completion
Jul 2011
Completion
Jul 2011
Last update
Dec 12, 2017

Study contacts

Freny V Mody, MD
principal investigator · VA Greater Los Angeles Healthcare System

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psyllium

Start the discussion